Can the ResMed share price smash its all-time high?

The ResMed Inc. (ASX: RMD) share price is down 18% from its all-time high, which may represent a buying opportunity.

| More on:
a woman

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

A leading company in an important industry ResMed Inc. (ASX: RMD) is a leader in the sleep treatment market, with a range of cloud enabled products designed to care for people with sleep apnea, COPD and other chronic diseases. This leading position has resulted in the the company's share price growing at an annualised rate of 17.9% over the last decade, excluding dividends.

Healthcare continues to rise in importance as a major topic on social and political agendas around the world. Aging populations, an increase in chronic disease, growing costs and a shortage of doctors require better solutions and technologies.

Despite this the ResMed share price dropped after an underwhelming second quarter result, delivered on 24 January 2019. For Q2 the company delivered 9% revenue growth to $651 million (on a constant currency basis) and Non-GAAP operating profit growth of 15%, to $181 million.

Capital allocation

It is pleasing to see the company focus on the long term, with a stated strategy to 2025. ResMed invests approximately 7% of its revenue back into research & development. This helps the company maintain and grow its market share through its range of quality products.

ResMed isn't just investing in itself however, with a number of acquisitions being made in recent years. The company has made numerous acquisitions in its key field of sleep apnea – most recently the purchase of South Korean based HB Healthcare, on 7 March 2019. ResMed has also invested in emerging areas such as out-of-hospital software-as-a-service offerings, through its 5 November 2018 acquisition of MatrixCare. The strategic decisions on the growing digital health and software-as-a-service trends highlights an understanding of where healthcare is moving.

The patent dispute

One concern that was lingering with ResMed until 21 February 2019 was the ongoing patent infringement dispute between ResMed and Fisher & Paykel Healthcare Corp Limited (ASX: FPH). In February both companies agreed to settle all of their outstanding patent infringement disputes, in all venues around the world. Most of the terms are confidential however, all ongoing proceedings ceased and both companies are paying their own legal expenses.

Foolish bottom line

ResMed has a long runway for growth, with sleep apnea being a grossly under-diagnosed medical condition. As doctors and potential patients alike become more aware of the condition, ResMed should see a steady increase in the adoption of its CPAP machines and its share price.

ResMed will report its third quarter FY19 earnings on 2 May 2019.

If you like the sound of ResMed, here are some other high quality growth companies.

Motley Fool contributor Lloyd Prout owns shares in ResMed. The Motley Fool Australia has recommended ResMed Inc. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Share Fallers

A male investor wearing a blue shirt looks off to the side with a miffed look on his face as the share price declines.
Share Fallers

Why DroneShield, Gentrack, Metals X, and Northern Star shares are tumbling today

These shares are ending the week in the red. But why?

Read more »

A man sits in despair at his computer with his hands either side of his head, staring into the screen with a pained and anguished look on his face, in a home office setting.
Share Fallers

Why Bapcor, Boss Energy, Macquarie, and Novonix shares are falling today

These shares are having a tough session on Thursday. But why?

Read more »

Stock market crash concept of young man screaming at laptop on the sofa.
Share Fallers

Guess which ASX 200 stock just crashed 31% on slumping sales

The $1.3 billion ASX 200 stock is getting hammered today.

Read more »

Frustrated stock trader screaming while looking at mobile phone, symbolising a falling share price.
Share Fallers

Why CBA, Inghams, Praemium, and Strike Energy shares are tumbling today

These shares are having a tough time on Tuesday. But why?

Read more »

Man with a hand on his head looks at a red stock market chart showing a falling share price.
Share Fallers

Why Brightstar, Eagers Automotive, Regis Resources, and Westpac shares are sinking

These shares are starting the week in the red. But why?

Read more »

Disappointed man with his head on his hand looking at a falling share price his a laptop.
Share Fallers

Why 29Metals, Atlas Arteria, DroneShield, and Yancoal shares are falling today

Let's see why these shares are ending the week in the red.

Read more »

Shot of a young businesswoman looking stressed out while working in an office.
Share Fallers

Why 29Metals, CAR Group, DroneShield, and Santana Minerals shares are falling today

These shares are missing out on the good times on Thursday. But why?

Read more »

Frustrated stock trader screaming while looking at mobile phone, symbolising a falling share price.
Share Fallers

Why Imricor, Imugene, Newmont, and Pepper Money shares are falling today

These shares are having a tough time on hump day. But why?

Read more »